Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.4 - $0.56 $5,412 - $7,577
-13,531 Reduced 38.57%
21,553 $8,000
Q1 2024

May 15, 2024

SELL
$0.53 - $1.89 $726 - $2,589
-1,370 Reduced 3.76%
35,084 $18,000
Q4 2023

Feb 14, 2024

BUY
$1.22 - $5.24 $34,290 - $147,280
28,107 Added 336.73%
36,454 $45,000
Q2 2023

Aug 14, 2023

SELL
$4.09 - $8.29 $66,458 - $134,704
-16,249 Reduced 66.06%
8,347 $35,000
Q1 2023

May 12, 2023

BUY
$4.89 - $10.53 $30,014 - $64,633
6,138 Added 33.25%
24,596 $198,000
Q4 2022

Feb 10, 2023

BUY
$3.86 - $42.0 $71,247 - $775,236
18,458 New
18,458 $143,000
Q1 2022

May 16, 2022

BUY
$2.74 - $5.65 $6,028 - $12,430
2,200 New
2,200 $10,000
Q4 2021

Feb 08, 2022

SELL
$4.41 - $6.99 $4,820 - $7,640
-1,093 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$6.69 - $16.93 $7,312 - $18,504
1,093 New
1,093 $7,000

Others Institutions Holding BIVI

About BIOVIE INC.


  • Ticker BIVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,165,300
  • Market Cap $86.3M
  • Description
  • BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...
More about BIVI
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.